547 related articles for article (PubMed ID: 16445378)
1. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
[TBL] [Abstract][Full Text] [Related]
2. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
3. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
4. Innovative approaches to the hormonal treatment of advanced prostate cancer.
Trachtenberg J
Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
[TBL] [Abstract][Full Text] [Related]
5. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
6. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
8. Novel secondary hormonal therapy in advanced prostate cancer: an update.
Van Allen EM; Ryan CJ
Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
[TBL] [Abstract][Full Text] [Related]
9. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for prostate cancer: current status and future prospects.
Miyamoto H; Messing EM; Chang C
Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
[TBL] [Abstract][Full Text] [Related]
11. Endocrine therapy for prostate cancer.
Labrie F
Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180
[TBL] [Abstract][Full Text] [Related]
12. Intra-prostatic androgen levels during various androgen-blockade regimens.
Nishiyama T
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
[TBL] [Abstract][Full Text] [Related]
13. Overview of enzyme inhibitors and anti-androgens in prostatic cancer.
Geller J
J Androl; 1991; 12(6):364-71. PubMed ID: 1769904
[TBL] [Abstract][Full Text] [Related]
14. Endocrine therapy for prostate cancer.
Sagalowsky AI
Spec Top Endocrinol Metab; 1985; 7():101-29. PubMed ID: 3914094
[TBL] [Abstract][Full Text] [Related]
15. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
Titus MA; Schell MJ; Lih FB; Tomer KB; Mohler JL
Clin Cancer Res; 2005 Jul; 11(13):4653-7. PubMed ID: 16000557
[TBL] [Abstract][Full Text] [Related]
16. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
Nishiyama T; Kanazawa S; Watanabe R; Terunuma M; Takahashi K
Int J Urol; 2004 Sep; 11(9):735-41. PubMed ID: 15379937
[TBL] [Abstract][Full Text] [Related]
17. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
Taplin ME
Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
[TBL] [Abstract][Full Text] [Related]
18. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
Middleman MN; Lush RM; Figg WD
Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
[TBL] [Abstract][Full Text] [Related]
19. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
20. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]